Press Releases

The Assistance Fund Opens New Program for Tumor-Induced Osteomalacia


Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Tumor-Induced Osteomalacia

ORLANDO, Fla., October 14, 2020 —The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for people living with tumor-induced osteomalacia (TIO). The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment, such as copayments, health insurance premiums, and incidental medical expenses related to the condition.

Tumor-induced osteomalacia is a rare disease that occurs when small tumors grow in the skin, muscles, or bones. TIO, sometimes referred to as oncogenic osteomalacia, results in weakened bones and kidneys, as well as elevated levels of urine. It is unclear what causes this serious condition. Individuals with TIO experience bone weakness and require surgery, and many years of treatment, for the condition.

“The Assistance Fund is excited to announce the launch of our new Tumor-Induced Osteomalacia Financial Assistance Program,” said Mark P. McGreevy, President and CEO of The Assistance Fund. “People living with tumor-induced osteomalacia not only face the challenge of an often debilitating diagnosis, they also must grapple with financial barriers to critical treatment. I’m grateful to our generous donors for allowing us to provide reassurance to so many in need.”

To learn more or determine eligibility for financial support, visit or call (855) 516-0080 to speak with a Patient Advocate.

A list of all the disease programs available from The Assistance Fund can be found on the website

About The Assistance Fund

The Assistance Fund is an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses. The Assistance Fund currently manages more than 70 disease programs, each of which covers the FDA-approved medications that treat a specific disease. Since our founding in 2009, The Assistance Fund has helped nearly 125,000 children and adults access critical treatment for a life-threatening, chronic, or rare disease. To learn more about The Assistance Fund, or for information on how to donate, please visit

Media Contact
Margaret Figley
Director of Communications

¹ “Oncogenic osteomalacia.” Genetic and Rare Diseases Information Center. (May 27, 2020). Retrieved from:

Share This
Categories: Press Releases